DRMA Dermata Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1853816 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-7.4%
TTM EPS YoY-121.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-241.5%
ROA-162.3%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets41.1%
Debt / equity0.00x
Current ratio—
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.93x
Accruals ratio-10.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $74,137 | — | — | — | — | — | — | — |
| Cost of revenue | $34,008 | — | — | — | — | — | — | — |
| Gross profit | $40,129 | — | — | — | — | — | — | — |
| R&D expense | $143,294 | $212,563 | $383,724 | $526,620 | $504,387 | $617,835 | $1.28M | $2.19M |
| SG&A expense | $2.76M | $2.80M | $1.54M | $1.37M | $1.26M | $1.15M | $1.06M | $1.01M |
| Operating income | -$2.86M | -$3.01M | -$1.93M | -$1.90M | -$1.76M | -$1.77M | -$2.34M | -$3.20M |
| Net income | -$2.82M | -$2.97M | -$1.85M | -$1.86M | -$1.69M | -$1.70M | -$2.30M | -$3.15M |
| EPS (basic) | -0.55 | -0.74 | -0.48 | — | -1.65 | -1.22 | -4.47 | — |
| EPS (diluted) | -0.55 | -0.74 | -0.48 | — | -1.65 | -1.66 | -4.47 | — |
| Weighted avg. shares (diluted) | 5.12M | 4.02M | 3.86M | — | 1.03M | 1.03M | 515,465 | — |
| Balance sheet | ||||||||
| Cash & equivalents | $4.82M | $4.41M | $6.95M | $7.52M | $4.66M | $6.48M | $9.72M | $3.16M |
| Inventory | $825,279 | $149,734 | $93,091 | — | — | — | — | — |
| Current assets | $6.43M | $5.16M | — | $7.86M | — | — | — | — |
| PP&E, net | $158,904 | $129,367 | — | — | — | — | — | — |
| Total assets | $6.64M | $5.32M | $7.47M | $7.86M | $5.07M | $6.64M | $10.01M | $3.53M |
| Total liabilities | $2.73M | $1.83M | $1.05M | $1.64M | $1.11M | $1.03M | $2.70M | $1.97M |
| Shareholders' equity | $3.91M | $3.49M | $6.41M | $6.22M | $3.96M | $5.61M | $7.30M | $1.56M |
| Shares outstanding | 4.93M | 4.02M | 4.02M | 2.66M | 844,457 | 637,757 | 6.03M | 251,725 |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.65M | -$2.42M | -$2.48M | -$1.33M | -$1.80M | -$2.69M | -$1.93M | -$2.91M |
| Capital expenditure | $52,980 | — | — | — | — | — | — | — |
| Free cash flow | -$2.70M | — | — | — | — | — | — | — |
| Investing cash flow | -$52,980 | — | — | — | — | — | — | — |
| Financing cash flow | $3.31M | -$323 | $1.90M | $4.19M | -$12,988 | -$547,857 | $8.49M | -$68,568 |
| Stock-based compensation | $42,179 | $41,780 | $43,278 | $29,469 | $37,840 | $39,234 | $37,189 | $29,815 |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.